Objective To understand the clinical efficacy and adverse reactions of elbasvir/grazoprevir in the treatment of hepatitis C virus (HCV) 1b infection in dialysis patients. Methods Clinical data of 3 dialysis patients with HCV 1b infection who were treated with elbasvir/grazoprevir were collected retrospectively, related literatures were consulted, analyzed and summarized. Results Two hemodialysis patients and one peritoneal dialysis patient were treated with antiviral therapy of elbasvir/grazoprevir, all of them achieved sustained virological response at 12 weeks (SVR12) and achieved the goal of clinical cure. One patient showed a significant decrease in hemoglobin after 4 weeks of treatment, but released after 12 weeks of treatment. Another patient had fatigue during the treatment,symptom disappeared after treatment. None of the three patients stopped the treatment due to complications. Conclusion Elbasvir/grazoprevir is effective for treating HCV 1b infection in hemodialysis and peritoneal dialysis patients, there is no serious adverse reaction.